Collective launches Zero Interest Option Exercise Loan Read More

Carmot Therapeutics stock

Carmot Therapeutics Stock

HealthTech
Looking to sell Carmot Therapeutics Stock or Options? Get a free valuation
Founded: 2008Funding to Date: $372M
Visit website

Carmot Therapeutics Inc, a clinical-stage biotech firm, is committed to creating transformative treatments for individuals suffering from metabolic disorders such as obesity and diabetes. The company has three clinical-stage product candidates in its pipeline: CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist for combating obesity and type 2 diabetes (T2D); CT-996, a once-daily oral small molecule GLP-1 receptor agonist also aimed at treating obesity and T2D; and CT-868, a once-daily injectable dual GLP-

Investors Include:

5AM Ventures, Ponoi Capital, TCG Crossover Management, Michael J. Fox Foundation, Amgen, RA Capital Management, Millennium Management, National Science Foundation, Willett Advisors, Venrock, National Cancer Institute, Franklin Templeton, Deep Track Capital, Janus Henderson Investors, Horizons Ventures, QB3, The Column Group, Qualifying Therapeutic Discovery Project, Jerome Dahan, Frazier Lifesciences Acquisition.

Own Carmot Therapeutics stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure